
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences Inc. has a promising outlook due to the potential monetization of its lead candidate, zetomipzomib, through strategic business development opportunities, particularly in the underserved area of autoimmune hepatitis (AIH). The company may benefit from the FDA's decision to allow patients to complete the Phase 2a PORTOLA trial, indicating a supportive regulatory environment that could lead to further data emergence and advancements in treatment for AIH. Additionally, the company’s focus on unmet medical needs in both autoimmunity and cancer positions it well for growth and valuation enhancements, especially if its other programs show positive developments.
Bears say
Kezar Life Sciences Inc. is projected to experience a significant financial burden, with a forecasted full-year 2024 net loss of $2.02 per share, reflecting continued operational challenges. The company recorded a 3Q24 net loss of $2.78 per share, which was substantially wider than previous estimates and highlights difficulties in managing expenses during a critical phase of development. Additionally, the board's rejection of a cash acquisition offer suggests a strategic misalignment and concerns regarding the company's valuation, further contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares